Yagi Toshinari, Suzuki Osamu, Matsuoka Haruki, Shinyashiki Kei, Wakamatsu Toru, Tamiya Hironari, Suzuki Rie, Kakunaga Shigeki, Takenaka Satoshi, Hashii Yoshiko, Yoshida Ken-Ichi, Nakanishi Katsuyuki
Department of Outpatient Chemotherapy, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan.
Osaka Heavy Ion Therapy Center, 3-1-10 Otemae, Chuo-ku, Osaka 540-0008, Japan.
Radiol Case Rep. 2024 Apr 16;19(7):2674-2678. doi: 10.1016/j.radcr.2024.03.070. eCollection 2024 Jul.
fusion sarcoma is a type of round-cell sarcoma with fusion that was newly categorized in the 2020 World Health Organization classification of soft tissue and bone tumors. In general, local disease is managed via surgical resection; however, at present, there is no standard therapy for locally advanced or metastatic disease. Here, we report our experience with a middle-aged male patient with pelvic fusion sarcoma who was treated with carbon ion radiotherapy and maintained stable disease for 13 months. The patient's clinical course suggests that carbon ion radiotherapy may be effective in patients with locally advanced fusion sarcoma.
融合肉瘤是一种具有融合特征的圆形细胞肉瘤，在2020年世界卫生组织软组织和骨肿瘤分类中被重新归类。一般来说，局部疾病通过手术切除进行治疗；然而，目前对于局部晚期或转移性疾病尚无标准治疗方法。在此，我们报告了一名中年男性盆腔融合肉瘤患者的治疗经验，该患者接受了碳离子放疗，疾病稳定维持了13个月。该患者的临床病程表明，碳离子放疗可能对局部晚期融合肉瘤患者有效。
